Molecular characterization of mutation in the parC and gyrB genes that confer fluoroquinolone resistance in Streptococcus pneumonia isolates
Yousef, L., Ismael, G., Mohammed, A., Mahmoud, M. (2018). Molecular characterization of mutation in the parC and gyrB genes that confer fluoroquinolone resistance in Streptococcus pneumonia isolates. EKB Journal Management System, 22(1), 321-334. doi: 10.21608/smj.2018.41821
Laila M Yousef; Ghada A Ismael; Ashraf k Mohammed; Mohammed H Mahmoud. "Molecular characterization of mutation in the parC and gyrB genes that confer fluoroquinolone resistance in Streptococcus pneumonia isolates". EKB Journal Management System, 22, 1, 2018, 321-334. doi: 10.21608/smj.2018.41821
Yousef, L., Ismael, G., Mohammed, A., Mahmoud, M. (2018). 'Molecular characterization of mutation in the parC and gyrB genes that confer fluoroquinolone resistance in Streptococcus pneumonia isolates', EKB Journal Management System, 22(1), pp. 321-334. doi: 10.21608/smj.2018.41821
Yousef, L., Ismael, G., Mohammed, A., Mahmoud, M. Molecular characterization of mutation in the parC and gyrB genes that confer fluoroquinolone resistance in Streptococcus pneumonia isolates. EKB Journal Management System, 2018; 22(1): 321-334. doi: 10.21608/smj.2018.41821

Molecular characterization of mutation in the parC and gyrB genes that confer fluoroquinolone resistance in Streptococcus pneumonia isolates

Sohag Medical Journal
Article 47, Volume 22, Issue 1, January 2018, Page 321-334  XML PDF (107.65 K)
Document Type: Original Article
DOI: 10.21608/smj.2018.41821
View on SCiNiTO View on SCiNiTO
Authors
Laila M Yousef1; Ghada A Ismael2; Ashraf k Mohammed3; Mohammed H Mahmoud3
1Department of Clinical and Chemical pathology, Faculty of Medicine, Sohag University.
2Department of Clinical Pathology, Faculty of Medicine, Ain Shams University.
3Department of Clinical Pathology, Faculty of Medicine, Sohag University.
Abstract
Resistance of Streptococcus pneumoniae to multiple antibacterial agents, including β-lactams, macrolides, tetracyclines, and co-trimoxazole, has emerged worldwide in the 1980s and 1990s and has emphasized the need for new therapeutic alternatives, such as newer fluoroquinolones. Older fluoroquinolones, such as ciprofloxacin and ofloxacin, have been widely used in the last 2 decades, but their activity against gram-positive pathogens is limited. Newer fluoroquinolones, such as levofloxacin, gatifloxacin, moxifloxacin, and gemifloxacin, have enhanced activity against most respiratory pathogens, and some are being more widely used to treat respiratory tract infections. Therefore, the emergence of fluoroquinolone-resistant S. pneumoniae strains, although worldwide prevalence is low, is a concern to clinicians who manage respiratory tract infections.
Aim of the work: The aim of this study was to determine the prevalence of fluoroquinolone resistance Streptococcus pneumoniae (FQRSP) and to examine the genetic relatedness of pneumococcal isolates with parC and gyrB genes mutations in different specimens.
Patients and Methods: In this study, Biometra Thermal Cyclar-T Gradient Software PCR system version 4 together with DNASIS 2.6 Sequence Analysis Programs were used to investigate the presence of mutations at quinolone resistance-determining regions of topoisomerase IV and DNA gyrase on 78 S. pneumoniae strains, Among 78 isolates 37 (47.4%) of S. pneumonia isolates were Fluroquinolones susceptible, 12 (15.4%) were with variable susceptibility and 29 (37.2%) were Fluroquinolones resistant.
Results: Our study illustrate the role of mutation in the parC & gyrB genes and the effect of mutations in the both genes in fluoroquinolone resistance among S. pneumoniae isolates.
Conclusion: Results indicated that there is a significant correlation between quinolone resistance development and mutations in the parC gene and in less significance in the gyrB genes .
Keywords
GyrB; ParC; Streptococcus pneumonia; Fluoroquinolones
Supplementary Files
References

1.  Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007;44 Suppl 2:S27-72.

2.  Patel SN, McGeer A, Melano R, Tyrrell GJ, Green K, Pillai DR, et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrobial agents and chemotherapy. 2011;55(8):3703-8.

3.  Morrissey I, Farrell DJ, Bakker S, Buckridge S, Felmingham D. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong. Antimicrobial agents and chemotherapy. 2003;47(4):1433-5.

4.  de la Campa AG, Balsalobre L, Ardanuy C, Fenoll A, Perez-Trallero E, Linares J, et al. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerging infectious diseases. 2004;10(10):1751-9.

5.  Fisher LM, Gould KA, Pan XS, Patel S, Heaton VJ. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. The Journal of antimicrobial chemotherapy. 2003;52(2):312-3; author reply 3-4.

6. Andersson MI, MacGowan AP. Development of the quinolones. The Journal of antimicrobial chemotherapy. 2003;51 Suppl 1:1-11.

7. Collins MD, Hutson RA, Hoyles L, Falsen E, Nikolaitchouk N, Foster G. Streptococcus ovis sp. nov., isolated from sheep. International journal of systematic and evolutionary microbiology. 2001;51(Pt 3):1147-50.

8. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrobial agents and chemotherapy. 2003;47(6):1867-74.

9. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001;293(5529):498-506.

10. Hoskins J, Alborn WE, Jr., Arnold J, Blaszczak LC, Burgett S, DeHoff BS, et al. Genome of the bacterium Streptococcus pneumoniae strain R6. Journal of bacteriology. 2001;183(19):5709-17.

11. Kargar M, Moein Jahromi F, Doosti A, Handali S. Molecular Investigation of Quinolone Resistance of Quinolone Resistance-Determining Region in Streptococcus pneumoniae Strains Isolated from Iran Using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Method. Osong public health and research perspectives. 2014;5(5):245-50.

12.  Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrobial agents and chemotherapy. 2000;44(11):3049-54.

13. Broskey J, Coleman K, Gwynn MN, McCloskey L, Traini C, Voelker L, et al. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. The Journal of antimicrobial chemotherapy. 2000;45 Suppl 1:95-9.

14. Brueggemann AB, Coffman SL, Rhomberg P, Huynh H, Almer L, Nilius A, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrobial agents and chemotherapy. 2002;46(3):680-8.

15. Beekmann SE, Heilmann KP, Richter SS, Garcia-de-Lomas J, Doern GV, Group GS. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. International journal of antimicrobial agents. 2005;25(2):148-56.

16.  Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, et al. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrobial agents and chemotherapy. 2000;44(2):462-6.

17.  Korzheva N, Davies TA, Goldschmidt R. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Antimicrobial agents and chemotherapy. 2005;49(6):2479-86.

18.  Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrobial agents and chemotherapy. 2002;46(1):119-24.

19.  Lim S, Bast D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerging infectious diseases. 2003;9(7):833-7.

20.  Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2005;41(2):139-48.

21.  De Vecchi E, Nicola L, Ossola F, Drago L. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations. The Journal of antimicrobial chemotherapy. 2009;63(4):721-7.

22.  Sierra JM, Cabeza JG, Ruiz Chaler M, Montero T, Hernandez J, Mensa J, et al. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2005;11(9):750-8.

23.  Brino L, Urzhumtsev A, Mousli M, Bronner C, Mitschler A, Oudet P, et al. Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center. The Journal of biological chemistry. 2000;275(13):9468-75.

24. Fass D, Bogden CE, Berger JM. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nature structural biology. 1999;6(4):322-6.

25.  Hosaka M, Kinoshita S, Toyama A, Otsuki M, Nishino T. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. The Journal of antimicrobial chemotherapy. 1995;36(2):293-301.

26.  Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrobial agents and chemotherapy. 1998;42(8):2060-5.

27.  Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrobial agents and chemotherapy. 1990;34(6):1271-2.

28.  Fukushima KY, Hirakata Y, Sugahara K, Yanagihara K, Kondo A, Kohno S, et al. Rapid screening of topoisomerase gene mutations by a novel melting curve analysis method for early warning of fluoroquinolone-resistant Streptococcus pneumoniae emergence. Journal of clinical microbiology. 2006;44(12):4553-8.

Statistics
Article View: 136
PDF Download: 214